Trial Profile
Effects of Atomoxetine and Oros-mph on Executive Functions in Patients With Combined Type Attention Deficit Hyperactivity Disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Feb 2015
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary) ; Methylphenidate
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 07 Feb 2015 New trial record